Uridine triphosphate

Oligonucleotide Synthesis, Modification, and Purification Services Market worth $6.53 Billion by 2030 - Exclusive Report by InsightAce Analytic

Retrieved on: 
Tuesday, July 5, 2022
GE Healthcare, Integrated DNA Technologies, Medication, Research, NGS, Hospital, COVID-19, Growth, Uridine, Diagnosis, Mass spectrometry, Vaccine, Molecular biology, Lists of diseases, Oligonucleotide, RNA transfection, Integration, CMOS, GMP, Thermo Fisher Scientific, Dharmacon, CAGR, RNA, Mirna, Contract, SNP, Biotechnology, Wuxi, LC, Viral Research and Diagnostic Laboratories, Merck Millipore, University of Sheffield, Sheffield, PCR, Degenerative disease, Nucleotide, CDMO, OEM, Bio-Synthesis, Inc., University, Biochemistry, DNA, Regulus Therapeutics, Medicine, Uridine triphosphate, Agilent Technologies, Fine chemical

Ltd. announces the release of a market assessment report on the " Global Oligonucleotide Synthesis, Modification and Purification Services Market Oligonucleotide Mfg.

Key Points: 
  • Ltd. announces the release of a market assessment report on the " Global Oligonucleotide Synthesis, Modification and Purification Services Market Oligonucleotide Mfg.
  • According to the latest research by InsightAce Analytic, the global oligonucleotide synthesis, modification, and purification services market is valued at US$ 1.56 billion in 2021, and it is expected to reach US$ 6.53 billion by 2030 with a CAGR of 17.50% during a forecast period of 2022-30.
  • Recently, there has been an augmented interest in involving modified oligoribonucleotides in molecular biology, biochemistry, and medicine.
  • However, the high expenses for the purification process, complex manufacturing procedures, oligo-degradation in the generic research, in-house development of oligonucleotides may hinder the growth of the global oligonucleotide synthesis, modification, and purification services market.

TriLink BioTechnologies® Extends EyeGene Partnership for COVID-19 Vaccine Development in South Korea

Retrieved on: 
Monday, October 4, 2021
Test pilot, GMP, KORUS, RNA transfection, Organic acid, Uridine, Vaccine, CDMO, Therapy, Annual report, CGMP, Security (finance), MFDS, Uridine triphosphate, U.S. Securities and Exchange Commission, Melamaravakkadu, Eye, Â, Korean Ministry of Culture, UTP, Degenerative disease, Private Securities Litigation Reform Act, COVID, SAN, COVID-19, Technology, Biotechnology, Research, Safety, Nasdaq, Industry, GLOBE, Pharmaceutical industry

This collaboration with EyeGene is expected to represent the first clinical-stage program to use GMP-grade modified uridine triphosphate, with an intended use for further processing, manufactured by TriLink.

Key Points: 
  • This collaboration with EyeGene is expected to represent the first clinical-stage program to use GMP-grade modified uridine triphosphate, with an intended use for further processing, manufactured by TriLink.
  • As part of these efforts, TriLink is excited to be expanding its collaboration with EyeGene in South Korea.
  • TriLink and EyeGene met on September 21, 2021, at the KORUS Global Vaccine Business Roundtable held in New York, to discuss their continued collaboration as EyeGene advances development of its vaccine into phase 1 clinical testing and beyond.
  • EyeGene took its first step in the development of innovative biopharmaceutical drugs when it was first established in June 2000.